The new public health crises were threatening the world with the emergence and spread of patients suffering from novel coronavirus (SARS-CoV-2). The epicentre of this highly contagious disease was Wuhan city, China, in December 2019. The World Health Organization (WHO) has verified the outbreak of novel coronavirus (2019-nCoV) as a global public health emergency of International Concern (PHEIC) (2). Currently, the major concern and clinical research on novel Coronavirus is inadequate or still in the primary stage Urgent need to develop safe and effective countermeasures that can be available, accessible and suitable for use in populations most in need. The outbreak is associated with exposures that surfaced in a Chinese seafood wholesale market. The novel virus, previously called the 2019-novel coronavirus (2019- nCoV), is currently designated as the severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), WHO officially named the disease COVID-19 in February 2020 and is registered by International Committee on Taxonomy of Viruses (ICTV). The observed variability in susceptibility to SARS-CoV-2 and severity of the ensuing COVID-19 have raised intense interest in their environmental and genetic risk factors. An early report from China suggested that blood group A was associated with increased susceptibility and blood group O was associated with reduced susceptibility to SARS-CoV-2 infection